4 reports

  • PHASE II
  • 9.1. CHAPTER OVERVIEW

MD Anderson Cancer Centre: One target that is very popular in this space is STAT##.

  • Cancer
  • Pharmaceutical
  • Therapy
  • Medicenna Therapeutics, Inc.
  • Novartis AG
  • PARTNERSHIPS
  • Apr 20, 2017: Medicenna to Present at Bloom Burton & Co. Healthcare Investor Conference 2017

Summary Medicenna Therapeutics Corp (Medicenna), formerly A2 Acquisition Corp, is a clinical stage immuno-oncology company.The company develops empowered cytokines (EC) and superkines for the treatment of cancer. Its pipeline products include MDNA55, MDNA109, MDNA209, MDNA57, MDNA413, and MDNA132.Medicenna also offers...

  • Cancer
  • Therapy
  • United States
  • Company
  • Medicenna Therapeutics, Inc.
  • PRODUCTS UNDER DEVELOPMENT BY COMPANIES, H1 2018
  • Toll Like Receptor 8 (CD288 or TLR8) - Therapeutics Development

In this trial, ## patients with PASI scores of ##. ## or greater will be randomized ##:##:##:## to receive weekly subcutaneous doses of IMO-## at ##. ##, ##. ##, or ##. ## mg/ kg/ week or placebo for ## weeks.

  • Cancer
  • Lymphoma
  • Pharmaceutical
  • Therapy
  • Idera Pharmaceuticals, Inc.
  • Toll Like Receptor 8 (CD288 or TLR8) - Therapeutics Development
  • Toll Like Receptor 8 (CD288 or TLR8) - Dormant Products

In this trial, ## patients with PASI scores of ##. ## or greater will be randomized ##:##:##:## to receive weekly subcutaneous doses of IMO-## at ##. ##, ##. ##, or ##. ## mg/ kg/ week or placebo for ## weeks.

  • Cancer
  • Lymphoma
  • Pharmaceutical
  • Therapy
  • Idera Pharmaceuticals, Inc.